Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial

SHR-1222, a novel humanized monoclonal antibody targeting sclerostin, has been shown to induce bone formation and decrease bone resorption at a single dose ranging 50–400 mg in our previous phase 1 trial. This study was a randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Zhijie, Zhu, Ronghua, Sheng, Zhifeng, Qin, Guijun, Luo, Xianghang, Qin, Qun, Song, Chunli, Li, Liping, Jin, Ping, Yang, Guoping, Cheng, Yanxiang, Peng, Danhong, Zou, Chong, Wang, Lijuan, Shentu, Jianzhong, Zhang, Qin, Zhang, Zhe, Yan, Xiang, Fang, Pingfei, Yan, Qiangyong, Yang, Lingfeng, Fan, Xiao, Liu, Wei, Wu, Bo, Cui, Rongrong, Wu, Xiyu, Xie, Yuting, Shu, Chang, Shen, Kai, Wei, Wenhua, Lu, Wei, Chen, Hong, Zhou, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116854/
https://www.ncbi.nlm.nih.gov/pubmed/37091850
http://dx.doi.org/10.3389/fendo.2023.1168757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116854/
https://www.ncbi.nlm.nih.gov/pubmed/37091850
http://dx.doi.org/10.3389/fendo.2023.1168757

Ejemplares similares